207 related articles for article (PubMed ID: 33798847)
41. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties.
Li T; Wang J; Feng L; Zhou Q; Xie Q; Shen Y; Ji R; Liu X; Wang Y; Hu C
Bioorg Chem; 2024 Jun; 147():107358. PubMed ID: 38626490
[TBL] [Abstract][Full Text] [Related]
42. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
43. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
44. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
[TBL] [Abstract][Full Text] [Related]
45. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
46. Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR-2 inhibition, and effects on the cell cycle profile.
Kassab AE; El-Dash Y; Gedawy EM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900319. PubMed ID: 32091161
[TBL] [Abstract][Full Text] [Related]
47. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents.
Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M
Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029
[TBL] [Abstract][Full Text] [Related]
48. Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors.
Mahnashi MH; Nahari M; Almasoudi H; Alhasaniah A; Elgazwi S; Abou-Salim MA
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2358934. PubMed ID: 38904116
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
50. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer.
Elimam DM; Elgazar AA; El-Senduny FF; El-Domany RA; Badria FA; Eldehna WM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):39-50. PubMed ID: 34894962
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
52. Biphenylurea/thiourea derivatives tagged with heteroarylsulfonamide motifs as novel VEGFR2 inhibitors; Design, synthesis and anti-angiogenic activity.
Al-Ansary GH; Nasr T; Taha H; Fayad W; Mahgoub S
Bioorg Chem; 2021 Feb; 107():104640. PubMed ID: 33485105
[TBL] [Abstract][Full Text] [Related]
53. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers.
Ghorab MM; Alsaid MS; Al-Ansary GH; Abdel-Latif GA; Abou El Ella DA
Eur J Med Chem; 2016 Nov; 124():946-958. PubMed ID: 27770735
[TBL] [Abstract][Full Text] [Related]
54. Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation.
El-Naggar M; Almahli H; Ibrahim HS; Eldehna WM; Abdel-Aziz HA
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914120
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
57. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
58. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
